Navigation Links
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
Date:2/13/2008

acquisition of Bioenvision,

Inc. in October 2007 and $(552,900)K related to our acquisition of

AnorMED Inc. in November 2006.

(6) Represents the write off of the goodwill related to our Genetics

reporting unit in September 2006 in accordance with FAS 142,

"Goodwill and Other Intangible Assets."

(7) Includes charges of $(570)K for the three months ended and $(21,102)K

for the year ended December 31, 2007 related to our completion of the

first step of the two step process under which we acquired

Bioenvision. In July 2007, we acquired approximately 22% of the

outstanding shares of Bioenvision common stock on an as-converted

basis, including all of the outstanding shares of Bioenvision

preferred stock for $(72,229)K of cash. Subsequently, in October

2007, following a favorable merger vote by Bioenvision's

shareholders, we completed the second step of the acquisition and,

effective October 23, 2007, acquired the remaining outstanding shares

of Bioenvision common stock for $(245,055)K of cash. In the fourth

quarter of 2007, we also paid $(11,975)K of cash for the outstanding

options to purchase shares of Bioenvision common stock. The full

purchase accounting for the acquisition of Bioenvision, including the

impact of the second step, is reflected in our consolidated financial

statements for the three months and year ended December 31, 2007 and

as of December 31, 2007.

(8) For the year ended December 31, 2007, includes a pre-tax gain of

$10,848K recorded on the sale of our entire investment in the common

stock of Therapeutic Human Polyclonals Inc. in March 2007, which had

a zero cost basis. For the year ended December 31, 2006, includes

pre- tax gains of $69,359K related to the liquidation
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine news :

1. Genzyme Receives FDA Response Letter on Synvisc-One(TM)
2. Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
3. Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
4. Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
5. Delaware Court Approves Bioenvision, Genzyme Joint Petition
6. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
7. Liquent Insight Publisher 3.6 Delivers Advanced Submission Capabilities
8. March of Dimes Delivers a New Look
9. Independence Blue Cross Delivers Important Reminder to Women during Cervical Cancer Awareness Month
10. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
11. Gleevec, the targeted cancer pill, delivers more good news to patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... that pull out all the stops to rescue surgical ... but the cost of such heroism is questionable, a ... 5 percent better at saving elderly patients with life-threatening ... with less intensity, said senior author Dr. Amir Ghaferi. ...
(Date:10/2/2014)... discovery by scientists at The University of Nottingham could ... of painkiller. , A drug resulting from the research, ... would offer new hope to sufferers of chronic pain ... effective painkillers are currently available. , The work, led ... Life Sciences, in collaboration with David Bates, Professor of ...
(Date:10/1/2014)... The peptide a small protein beta-amyloid is strongly associated ... unequivocal proof that this peptide is the causal agent ... main obstacle impeding such confirmation is that beta-amyloid is ... it aggregates, that is when it self-assembles to form ... with a single target, beta-amyloid alone, but with multiple ...
(Date:10/1/2014)... new research study published today in the Journal ... patients older than 50 years with moderate or severe ... , Researchers from the University of Melbourne randomly assigned ... pain to no acupuncture or sham or pretend laser ... with participants and acupuncturists blinded to laser and sham ...
(Date:10/1/2014)... co-funded by the Engineering and Physical Sciences Research ... the UK,s vital industrial control systems which run, ... grid, and the rail network. , The ... hackers or malware infiltrating the systems behind our ... in Trustworthy Industrial Control Systems (RITICS), based at ...
Breaking Medicine News(10 mins):Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Medical discovery first step on path to new painkillers 2Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2
... more likely it is to persist, experts say, , , FRIDAY, Sept. ... a harmless rite of passage. But new research suggests it has ... only are people who start to drink at a younger age ... likely to be injured, to be in motor vehicle crashes and ...
... Hopkins recently discovered that a chemical chain reaction that ... humans could mean the difference between normal growth and ... of Cell, describes how organs can grow uncontrollably huge ... , This chain reaction, a domino-like chain of ...
... results of a recent National Academy of Sciences report, ... be restored to the U.S. Department of Energy, says ... nuclear medicine professionals. , Funded by the Department of ... $700,000 report was prompted by a $23 million cut ...
... Roper Industries,Inc. (NYSE: ROP ) announced that ... September 30, 2007, will be released after the market ... discuss these results,has been scheduled for 10:00 AM ET ... via webcast or by dialing +1 888-801-6506 (US/Canada) or ...
... Sept. 21 ChemDiv, Inc. (San Diego) announced,today ... is,undertaking a partnership with the Blokhin Russian Oncology ... the US Department of Energy,(DOE), and the US ... therapies for the prevention and treatment of prostate ...
... LANSING, Mich., Sept. 21 On Sept. 18, ... annual Pinnacle Awards,for Best Practices award reception at ... for Best Practices. "Organizations such as these,are leading ... Pam Byrnes, Pinnacle judge, said. "Michigan needs more,health ...
Cached Medicine News:Health News:Teenage Drinking Can Spell Lasting Trouble 2Health News:Teenage Drinking Can Spell Lasting Trouble 3Health News:Controlling for size may also prevent cancer 2Health News:SNM applauds NAS study showing need to restore federal nuclear medicine research funding 2Health News:SNM applauds NAS study showing need to restore federal nuclear medicine research funding 3Health News:Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership 2Health News:Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership 3Health News:Eight Michigan HMOs, Two Providers, Take Top Honors for Quality Health Care 2Health News:Eight Michigan HMOs, Two Providers, Take Top Honors for Quality Health Care 3
(Date:9/30/2014)... , Sept. 30, 2014  Hologic, Inc. (NASDAQ: ... , Hologic,s President and Chief Executive Officer, will preside ... October 1, the first day of Breast Cancer Awareness ... Company,s campaign focused on the important benefits of Hologic,s ... the FDA as clinically superior to traditional mammography. ...
(Date:9/30/2014)... Md. , Sept. 30, 2014  Tasly ... way to modernize medicine, announced today the launch ... of nutraceuticals developed to address men and women ... healthy and vibrant into old age while helping ... includes three condition-specific, whole-food and herb-based formulas, namely, ...
(Date:9/30/2014)... Sept. 30, 2014 STUDY OBJECTIVES ... is to provide an overview of the current ... protein drugs/therapeutics. The key objective is to present ... drugs as an important tool in the treatment ... and future strategies within the protein therapeutics market, ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4
... , PITTSBURGH , June 17 Mylan ... Mylan Pharmaceuticals Inc. received final approval from the U.S. Food ... (ANDA) for Hydroxyzine Hydrochloride Tablets 10 mg, 25 mg and ... therefore, therapeutically equivalent to Pliva,s Hydroxyzine Hydrochloride Tablets, a treatment ...
... Copan unveiled new groundbreaking features of its Walk-Away Specimen ... American Society for Microbiology (ASM) in San Diego, California ... to the market in 2008 with the launch of the ... all microbiology samples. While attending the 110th ASM meeting, Copan ...
Cached Medicine Technology:Mylan Receives Approval for Hydroxyzine Hydrochloride Tablets 2Copan Redefines Automated Specimen Processing with Groundbreaking New Features 2Copan Redefines Automated Specimen Processing with Groundbreaking New Features 3
Suture Cutters, Straight...
Suture scissor...
Threaded cannula for use with Suretac® II, sterile packs, box of 10....
The Small Oval Cannula System is designed to be the smallest oval cannula system currently available, and is utilized with the Caspari Suture Punch System. Disposable seals are available with this sy...
Medicine Products: